Benjamin Oakes from Scribe Therapeutics shares how exciting advancements in CRISPR-based gene and epigenetic editing therapies impact the future of cardiovascular and cardiometabolic disease management.



Summary

Benjamin Oakes highlights the transformative potential of CRISPR technology, specifically gene and epigenetic editing, in revolutionizing cardiovascular and cardiometabolic disease treatment. He emphasizes the promise of precisely targeting and modifying genes or their expression to address the root causes of these complex conditions. This approach offers the possibility of more effective and potentially curative therapies compared to current treatments. Oakes paints a hopeful vision for the future where CRISPR-based therapies significantly improve patient outcomes and management strategies for heart and metabolic diseases.

Read more…

This post is part of “Science and Technology News”, Follow for more…!!!

Credits: Source

Disclaimer